Intersection of phenotypic plasticity and anoikis enhances therapeutic vulnerability in prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metastasis Research

Background:

• Cancer cells develop anoikis (apoptosis triggered by detachment) resistance to survive circulation during metastasis.
• Anoikis resistance is linked to treatment resistance and tumor recurrence in prostate cancer patients.
• Key signaling pathways (FAK, PI3K/AKT, MAPK, integrin) and genes (CDKN1A, NEDD9, CFL1, JAM2) are implicated in anoikis resistance and prostate cancer progression.

Purpose of the Study:

• To review current literature on cellular drivers of anoikis resistance in prostate cancer.
• To explore the intersection of anoikis resistance and phenotypic plasticity within the tumor microenvironment.
• To identify molecular mechanisms exploitable for therapeutic applications and predictive marker development.

Main Methods:

• Literature review of studies on anoikis resistance, phenotypic plasticity, and prostate cancer.
• Analysis of transcriptomic data identifying anoikis-centered genes.
• Interrogation of molecular pathways involved in cytoskeletal remodeling and cell cycle regulation.

Main Results:

• Anoikis resistance is a critical factor in cancer cell survival during metastasis.
• Genes like CDKN1A, NEDD9, CFL1, and JAM2 show prognostic value and correlate with therapeutic resistance.
• Molecular mechanisms involving cytoskeletal dynamics (cofilin, NEDD9) and cell cycle regulation (CDKN1A) are central to anoikis resistance.

Conclusions:

• Targeting anoikis resistance pathways presents a promising therapeutic strategy for advanced prostate cancer.
• Anoikis-resistance based signatures may serve as predictive markers for therapy resistance and recurrence.
• Further research into these molecular mechanisms can lead to novel translational applications for improved patient outcomes.